Related Experiment Video
Updated: May 12, 2026

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
Published on: October 12, 2012
Disease Activity After Switching From Eculizumab to Ravulizumab in Patients With Paroxysmal Nocturnal
Anders Rønneholt-Frederiksen1, Dennis Lund Hansen1,2, Vuokko Nummi3
1Department and Research Unit of Hematology Odense University Hospital Odense Denmark.
Introduction:
Ravulizumab replaced eculizumab as the preferred complement inhibitor for Paroxysmal Nocturnal Haemoglobinuria (PNH) in Denmark and Finland after 2020. Data on real-world disease activity after switching are limited.
Methods:
We conducted a case series of 20 PNH patients who transitioned from eculizumab to ravulizumab, assessing transfusion needs and breakthrough haemolysis episodes (BTH).
Results:
In 19 of 20 patients, transfusions and BTH were stable or reduced after switching. Particularly, patients with high transfusion or BTH burden had a marked reduction in these parameters after switching.
Conclusion:
Overall, ravulizumab provided comparable or improved disease control, supporting its use as a long-term treatment in PNH.
Trial Registration:
The authors have confirmed clinical trial registration is not needed for this submission.
More Related Videos
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

